Skip to main navigation
 
Zentalis

Top Navigation

  • About Us
    • Our Company
      • Management Team
      • Board of Directors
      • Scientific Advisory Board
      • Business Advisory Board
      • Partners & Collaborations
    • Contact Us
  • Our Pipeline
    • Pipeline
      • ZN-c3
      • ZN-c5
      • ZN-d5
      • ZN-e4
    • Clinical Trials
  • Our Approach
    • Integrated Discovery Engine
    • Supporting Publications
  • Investors & Media
    • Investor Home
    • News & Events
      • Press Releases
      • Events & Presentations
    • Stock Information
      • Stock Quote & Chart
      • Historic Price Lookup
      • Investment Calculator
      • Analyst Coverage
    • Financials & Filings
      • SEC Filings
    • Corporate Governance
      • Documents & Charters
      • Management Team
      • Board of Directors
      • Scientific Advisory Committee
      • Business Advisory Committee
      • Committee Composition
    • Investor Resources
      • Investor FAQs
      • Investor Contact
      • Email Alerts
  • Careers

Investors/Media

Press Releases

Press Releases

May 16, 2022
Zentalis Pharmaceuticals Announces Pricing of Underwritten Offering of Common Stock
May 16, 2022
Zentalis Pharmaceuticals Appoints Oncology Clinical Development Veteran Dr. Kimberly Blackwell as Chief Executive Officer
May 05, 2022
Zentalis Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Update
Apr 27, 2022
Zentalis Pharmaceuticals Announces $25 Million Equity Investment from Pfizer
Apr 11, 2022
Zentalis Pharmaceuticals Announces Overview of Clinical and Preclinical Data Presented at AACR
Apr 08, 2022
Zentalis Pharmaceuticals Announces Positive Initial Clinical Data on ZN-c3, its Wee1 Inhibitor, in Patients with Advanced Ovarian Cancer at AACR
Mar 29, 2022
Zentalis Pharmaceuticals and Caris Life Sciences Announce Strategic Collaboration to Support Clinical Studies, Initially Focused on the Wee1 Inhibitor ZN-c3
Mar 22, 2022
Zentalis Pharmaceuticals Announces First Patient Dosed in the Potentially Registrational Phase 1/2 Study of BCL-2 inhibitor ZN-d5 in Patients with Relapsed or Refractory Light Chain (AL) Amyloidosis
Mar 15, 2022
Stand Up to Cancer Announces $1 Million Donation From Zentalis Pharmaceuticals To Fund Targeted Cancer Therapy Research
Mar 09, 2022
Zentalis Pharmaceuticals to Present at the Oppenheimer Annual Healthcare Conference

Pagination

  • Current page 1
  • Page 2
  • Next page next ›
  • Last page last »
Displaying 1 - 10 of 13

Investors/Media

  • Investor Home
  • News & Events
    • Press Releases
    • Events & Presentations
  • Stock Information
    • Stock Quote & Chart
    • Historic Price Lookup
    • Investment Calculator
    • Analyst Coverage
  • Financials & Filings
    • SEC Filings
  • Corporate Governance
    • Documents & Charters
    • Management Team
    • Board of Directors
    • Scientific Advisory Committee
    • Business Advisory Committee
    • Committee Composition
  • Investor Resources
    • Investor FAQs
    • Investor Contact
    • Email Alerts

Investor Contact

Alexandra Roy
Solebury Trout
aroy@soleburytrout.com

Media Contact

Julia Deutsch
Solebury Trout
jdeutsch@soleburytrout.com

“The sun is but a morning star.”

Zentalis Logo

Corporate Office

530 Seventh Avenue
Suite 2201
New York, NY 10018

Science Center

10835 Road to the Cure
Suite 205
San Diego, CA 92121

For More Information

1-212-433-3791
info@zentalis.com

Footer

  • Privacy Policy
  • Terms of Use
  • Expanded Access Policy
  • Site Map

Copyright © 2022 Zentalis Pharmaceuticals. All Rights Reserved.